Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresh Start For Insmed, Added Biosimilar Capabilities For Merck In $130M Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

By purchasing Insmed’s follow-on biologics pipeline and facility, Merck BioVentures is poised for bigger attack on Amgen blockbusters.

You may also be interested in...



Insmed Gets New Direction By Absorbing Transave And Lead Program Arikace

Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.

Insmed Gets New Direction By Absorbing Transave And Lead Program Arikace

Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.

On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era

The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel